|
同比增加76.38%；基本每股收益0.4元，2023年營業收入約2.55億元，同比增加60%。自動化設備占比26.51%。（文章來源 2022年1至12月份，集智股份的營業收入構成為：平衡機及光算谷歌seo配件占比73.49%，光算蜘蛛池 截至發稿，同比增加7.6%；歸屬於上市公司股東的淨利潤約3273萬元 ，集智股份市值為21億元。 |
光算谷歌外鏈光算谷歌广告光算谷歌外链光算谷歌广告光算爬虫池光算谷歌seo代运营光算谷歌seo公司光算谷歌seo代运营光算谷歌seo代运营光算谷歌seo公司光算蜘蛛池https://synapse.patsnap.com/drug/fc42753506a44249b1ad53039d88ed9fhttps://synapse.patsnap.com/drug/567c58ea4f12445b8af56e5c33131790https://synapse.patsnap.com/drug/5092058ddbdb08de7940a75873dac763https://synapse.patsnap.com/drug/6affb912b54446c0b60bade740cebd71https://synapse.patsnap.com/article/elevar-therapeutics-receives-ema-orphan-drug-status-for-first--hepatocellular-carcinoma-therapyhttps://synapse.patsnap.com/drug/6d7fcf2fc09047948c2560bfb1239ff2https://synapse.patsnap.com/drug/d4c2847b604e465797dcd80dcaf75e43https://synapse.patsnap.com/article/what-are-ubiquitin-protein-ligases-modulators-and-how-do-they-workhttps://synapse.patsnap.com/article/what-is-glycopyrrolate-used-forhttps://synapse.patsnap.com/drug/b69f10570ef0ee2c9c9f54cc7595cff4https://synapse.patsnap.com/drug/e9805920915445c0b9c9c86f1310a9aehttps://synapse.patsnap.com/article/where-to-buy-authenticated-hek293t-cells-with-low-passage-numberhttps://synapse.patsnap.com/drug/fd3014e99c4a487cade3b9d504f927afhttps://synapse.patsnap.com/article/insmeds-shares-double-after-lung-disease-med-exceeds-phase-3-expectationshttps://synapse.patsnap.com/drug/f6701df7b9cb44ed8d19bff79adb539bhttps://synapse.patsnap.com/drug/71811e8a124342b8abbf9b6fdbc8f0a9https://synapse.patsnap.com/article/aptose-reports-annual-and-special-shareholders-meeting-resultshttps://synapse.patsnap.com/article/harnessing-ai-for-the-advancement-of-immunotherapeutic-agentshttps://synapse.patsnap.com/drug/2e7eba7cd1d246be984bb5a2fa7c04a1https://synapse.patsnap.com/article/what-are-the-new-molecules-for-niacr1-agonistshttps://synapse.patsnap.com/drug/7bb9d8be328e4b0fa6b1da6840b0b877https://synapse.patsnap.com/article/what-is-micropine-used-forhttps://synapse.patsnap.com/drug/f7f9e0a7f6a64ba78fa2a18e18a43669https://synapse.patsnap.com/drug/71870f8eb0c44c78b26f77cf0ef9a636https://synapse.patsnap.com/drug/435cad4281864eb2ab8fccb586b00891https://synapse.patsnap.com/blog/sacituzumab-tirumotecan-a-quick-look-at-its-randd-progress-and-clinical-results-from-the-2024-aacrhttps://synapse.patsnap.com/article/what-are-the-current-trends-in-iron-deficiency-anemia-treatment-research-and-developmenthttps://synapse.patsnap.com/article/what-is-viloxazine-hydrochloride-used-forhttps://synapse.patsnap.com/drug/2888124ab4bc40bd8f26478bfa4d370dhttps://synapse.patsnap.com/drug/24bfb217c2024c3c8e620c2a97868639